Global Neurostimulation Devices Market: Analysis and Forecast, 2021-2030
Global Neurostimulation Devices Market to Reach $18,033.0 Million by 2030
Market Report Coverage - Neurostimulation Devices
- By Product Type: Implantable and non-implantable
- Implantable neurostimulation devices can be further segmented into seven types - spinal cord stimulation, auditory brainstem implant, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, hypoglossal nerve stimulation, and others.
- Non-implantable neurostimulation devices can be further segmented into two types - transcranial magnetic stimulation, and others
- By Application: Pain management, hearing loss, Parkinson’s disease, epilepsy, urinary and fecal Incontinence, depression, and others
- North America –U.S. and Canada
- Europe – Germany, U.K., France, Italy, Spain, Russia, Switzerland, Rest-of-the-Europe
- Asia-Pacific – Japan, China, India, Australia, South Korea, Rest-of-the-Asia-Pacific
- Latin America- Brazil, Mexico, Argentina, and Rest-of-the-Latin America
- Middle East and Africa
Frequently Asked Questions (FAQs)
- Growing incidence of neurological disorders
- Increased side-effects of pain management medications in geriatric population
- Limited success rate of drugs targeting specific diseases
- Advent of sedentary lifestyles resulting massive burden of chronic pain
- Growing concerns pertaining to pelvic health of geriatric population
- Financial burden of product recalls
- Increased regulatory scrutiny
- High cost of equipment
- Evolution of biomarker-based therapeutics enabling early diagnostics of neurological disorders
- Development of closed loop neuromodulation
Key Companies Profiled
- Abbott Laboratories, Axonics Modulation Technologies, Inc., Beijing PINS Medical Co., Ltd., Boston Scientific Corporation, Cochlear Ltd., electroCore, Inc., Helius Medical Technologies, Inc., Inspire Medical Systems, Inc., Laborie Medical Technologies, Inc., LivaNova PLC, MED-EL, Medtronic plc, NeuroMetrix, Inc., NeuroPace, Inc., Nevro Corporation, Sonova, Synapse BioMedical, Inc., and The Magstim Company Limited
Key Questions Answered in this Report:
- What is a neurostimulation device? How have different neurostimulation devices evolved over the years?
- What are the advantages of non-invasive and minimally invasive neurostimulation devices?
- What are the major market drivers, challenges, and opportunities in the global neurostimulation devices market?
- What is the global neurostimulation devices market size in terms of revenue in 2020? What is the market size expected to be in 2030?
- How is each segment of the global neurostimulation devices market expected to grow during the forecast period between 2021 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
- What are the developmental strategies implemented by the key players to sustain in the competitive market?
- What is the growth potential of the neurostimulation devices market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?
- Which type of neurostimulation devices are expected to dominate the market in 2030, and why?
- Which key players of the neurostimulation devices market are expected to grow during the forecast period?
- Which neurostimulation technology is leading the market in 2019 and expected to dominate the market in 2030, and why?
- Which applications are leading the neurostimulation devices market in 2019 and are expected to dominate the market in 2030, and why?
- Which region dominated the global neurostimulation devices market in 2019 and what are the expected trends from each of the regions in the forecast period 2021-2030?
- What is the impact of COVID-19 on the neurostimulation devices market?
- What type of products coming in the upcoming years pertaining to neurostimulation devices?
Neurostimulation devices consider the implantable and non-implantable neurostimulation devices which act on the spinal cord and brain to deliver the electrical stimulation to a targeted area. These types of devices are mainly used in the treatment and management of Parkinson’s disease, bowel and bladder dysfunction, Alzheimer’s disease, and relieving chronic pain of the body. For carrying out innovative research in the field of neurostimulation devices, companies in the market received funding and investments by a few government organizations. The global neurostimulation devices market witnessed approximately 22 funding and investments in the past four years (January 2016-May 2020). For instance, NeuroPace, Inc. received $74 million funding from KCK Group and OrbiMed Advisors for ramping the production of NeuroPace RNS System, which was approved by the FDA in 2013. This device is used for the treatment and management of epileptic seizures.
The companies received a large number of product approvals by the regulatory bodies, including FDA, PMDA, Japan’s Ministry of Health, Labour and Welfare, CE mark certification, European Medical Device Regulation (MDR) certification, and TGA approvals. Medtronic plc, Helius Medical Technologies, BrainsWay, Nevro Corporation, and Cochlear Ltd. received the maximum number of product approvals. For instance, in January 2020, Medtronic plc received CE mark approval for the Percept PC neurostimulator DBS system with BrainSense Technology. This device is used for the treatment of Parkinson’s disease. Moreover., in March 2020, Helius Medical Technologies received approval from Health Canada to commercialize the PoNS Device. This device is used for the treatment and management of multiple sclerosis (MS).
The market is favored by multiple factors, which include rising prevalence of neurological diseases, such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and neuropathic pain. Neurostimulation devices have shown promising results to cure disorders that affect the activity of the nervous system that includes the brain and spinal cord. Furthermore, there are plenty of options available in the neurostimulation devices market offering preventive treatment against such conditions. Such products are therefore being adopted even by professionals and by people of different age groups. Hence, the results of the prevention and treatment of different neurological disorders are accelerating the growth of the neurostimulation devices market.
Elderly population is mostly under pain management treatment for different neurological disorders, which include Parkinson’s disease and Alzheimer’s disease. As in the geriatric population, they are likely to have an increased risk of adverse reactions from pharmacological methods which are used for pain management medications. Thus, such methods that are used for the treatment of neurostimulation disorders consist of minimally invasive methods used for the management of persistent pain and cause no side effects and risk. Addressing chronic diseases that have a high incidence in the geriatric population is expected to gain momentum due to this growing number and shall continue to drive the global neurostimulation devices market.
All these factors are thus, expected to contribute to market growth during the forecast period.
Within the research report, the market is segmented based on product type, application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to provide a 360-coverage of the domain.
Major players, including Medtronic plc, Boston Scientific Corporation, Cochlear, Ltd., and Abbott Laboratories, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. Based on the region, North America is expected to retain a leading position in the market throughout the forecast period 2021-2030, followed by Europe. North America’s market dominance, as well as the market growth in the region, can primarily be attributed to the presence of several established leading players including Abbott Laboratories, Boston Scientific Corporation, Inspire Medical Systems, Inc., Nuvectra Corporation, NeuroMetrix, Inc., among others that make the region one of the attractive markets for neurostimulation devices. These players have entered into strategic partnerships with the leading research centers and universities, and government medical research centers in the region to facilitate the development of their products. For instance, in May 2019, Abbott Laboratories partnered with NIH on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neurological science. Likewise, in January 2018, Helius Medical Technologies, Inc. partnered with Key Tronic corporation to provided contract manufacturing for portable neuromodulation stimulator (PoNS) devices.
BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.
With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.
Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
Similar Reports from BIS Research
Global Neurostimulation Devices Market: Focus on Technology Type, Application,17 Countries Data, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2024
The emergence of sedentary lifestyles, growing geriatric population, physical and mental stress have resulted in different healthcare concerns. Neurological disorders are one of the leading medical conditions which is contributing predominantly to the global healthcare market. The rising prevalence of different types of neurological disorders, a recurring requirement of neuromodulation therapies, and geriatric population medication are attributing to the growth ...